--- title: "Omeros | 10-K: FY2025 Revenue: USD 0" type: "News" locale: "en" url: "https://longbridge.com/en/news/281237922.md" datetime: "2026-03-31T20:18:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/281237922.md) - [en](https://longbridge.com/en/news/281237922.md) - [zh-HK](https://longbridge.com/zh-HK/news/281237922.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/281237922.md) | [繁體中文](https://longbridge.com/zh-HK/news/281237922.md) # Omeros | 10-K: FY2025 Revenue: USD 0 Revenue: As of FY2025, the actual value is USD 0. EPS: As of FY2025, the actual value is USD -0.05, beating the estimate of USD -1.2925. EBIT: As of FY2025, the actual value is USD -125.93 M. #### Net Loss Omeros Corporation reported a net loss of - $3,350 thousand for the year ended December 31, 2025, a significant improvement from a net loss of - $156,815 thousand in 2024 and - $117,813 thousand in 2023. #### Research and Development Expenses Total Research and Development (R&D) Expenses were $81,296 thousand in 2025, decreasing by $38,227 thousand from $119,523 thousand in 2024. In 2023, total R&D expenses were $114,870 thousand, an increase of $4,653 thousand from 2024 to 2023. **Direct External Expenses:** **Clinical Research and Development:** Total clinical R&D was $31,558 thousand in 2025, down from $65,084 thousand in 2024 and $64,607 thousand in 2023. Expenses for the MASP-3 program - OMS906 (zaltenibart) were $16,109 thousand in 2025, $24,997 thousand in 2024, and $22,853 thousand in 2023. Expenses for the MASP-2 program - OMS721 (narsoplimab) were $14,126 thousand in 2025, $35,913 thousand in 2024, and $35,352 thousand in 2023. MASP-2 program - OMS1029 and other expenses were $579 thousand in 2025, $4,059 thousand in 2024, and $6,249 thousand in 2023. PDE7 program - (NIDA) expenses were $744 thousand in 2025, $115 thousand in 2024, and $153 thousand in 2023. **Preclinical Research and Development:** Preclinical R&D expenses were $4,071 thousand in 2025, $6,465 thousand in 2024, and $5,172 thousand in 2023. **Internal, Overhead and Other Expenses:** These expenses totaled $42,137 thousand in 2025, $43,841 thousand in 2024, and $40,337 thousand in 2023. **Stock-Based Compensation Expenses (R&D):** Stock-based compensation for R&D was $3,530 thousand in 2025, $4,133 thousand in 2024, and $4,754 thousand in 2023. #### Selling, General and Administrative Expenses Total Selling, General and Administrative (SG&A) Expenses were $41,500 thousand in 2025, representing a decrease of $5,930 thousand from $47,430 thousand in 2024. SG&A expenses in 2024 decreased by $2,230 thousand from $49,660 thousand in 2023. **Excluding Stock-Based Compensation Expense:** SG&A expenses were $36,838 thousand in 2025, $41,070 thousand in 2024, and $42,520 thousand in 2023. **Stock-Based Compensation Expense (SG&A):** This component was $4,662 thousand in 2025, $6,360 thousand in 2024, and $7,140 thousand in 2023. #### Gain on Sale of Zaltenibart Omeros Corporation recorded a gain of $237,594 thousand from the sale of Zaltenibart in 2025, with no such gains in 2024 or 2023. #### Gain on Early Extinguishment of Term Debt, Net A net gain of $17,035 thousand from the early extinguishment of term debt was recognized in 2025, with no gains in prior years. #### Gain (Loss) on Early Extinguishment of 2026 Notes There was a loss of - $2,968 thousand on the early extinguishment of 2026 notes in 2025, compared to a gain of $4,112 thousand in 2023 and $0 thousand in 2024. #### Interest and Other Income Interest and other income was $4,096 thousand in 2025, $11,285 thousand in 2024, and $16,342 thousand in 2023. #### Interest Expense, Net of Remeasurement Adjustments and Other Interest expense was - $960 thousand in 2025, $24,675 thousand in 2024, and $30,844 thousand in 2023. #### Gain (Loss) on Change in Fair Value of Financial Instruments, Net A net loss of - $136,717 thousand was recorded in 2025, contrasting with a gain of $19 thousand in 2024 and $0 thousand in 2023. #### Income Tax Expense Income tax expense was - $2,012 thousand in 2025, - $2,305 thousand in 2024, and $0 thousand in 2023. #### Net Income from Discontinued Operations, Net of Tax (OMIDRIA) Net income from discontinued operations (OMIDRIA) was $1,458 thousand in 2025, significantly lower than $25,814 thousand in 2024 and $57,107 thousand in 2023. #### Cash Flow Data - **Operating Activities:** Net cash used in operating activities was - $116,094 thousand in 2025, decreasing by $32,709 thousand from - $148,803 thousand in 2024. In 2023, operating activities provided $74,726 thousand, which decreased by $223,529 thousand to 2024. - **Investing Activities:** Net cash provided by investing activities increased to $164,523 thousand in 2025 from $82,217 thousand in 2024, an increase of $82,306 thousand. In 2023, investing activities provided $27,454 thousand, increasing by $54,763 thousand to 2024. - **Financing Activities:** Net cash used in financing activities was - $42,169 thousand in 2025, an increase of $105,050 thousand from $62,881 thousand provided in 2024. In 2023, financing activities used - $106,084 thousand, which increased by $168,965 thousand to 2024. #### Cash, Cash Equivalents and Short-Term Investments As of December 31, 2025, cash, cash equivalents, and short-term investments totaled $171,804 thousand, up from $90,132 thousand as of December 31, 2024. #### Total Debt Total aggregate principal amount of debt was $87,862 thousand as of December 31, 2025, a decrease of $77,038 thousand or 46.7% from $164,900 thousand as of December 31, 2024. #### Outlook / Guidance Omeros Corporation anticipates funding over 12 months of operations using current cash, cash equivalents, and short-term investments, supplemented by expected commercial sales of YARTEMLEA. The company may also seek additional capital through equity, debt, royalty sales, or other strategic transactions. Research and development costs for 2026 are projected to be lower than in 2025 due to reduced clinical trial costs for zaltenibart and decreased drug manufacturing expenses, while selling, general and administrative expenses are expected to rise to support YARTEMLEA’s commercial launch. ### Related Stocks - [Omeros Corporation (OMER.US)](https://longbridge.com/en/quote/OMER.US.md) ## Related News & Research - [Omeros Turns Corner With Novo Deal, YARTEMLEA Launch](https://longbridge.com/en/news/281666535.md) - [OMER S.p.A.: Resilient Fundamentals and Structural Growth Support Buy Rating Despite Softer FY26 Outlook](https://longbridge.com/en/news/281649119.md) - [Blackstone to Acquire 49% Stake in Rowan Digital Infrastructure](https://longbridge.com/en/news/281742938.md) - [Wealth First Promoters Confirm 74% Stake With No Encumbrance in FY26](https://longbridge.com/en/news/281530653.md) - [Omeros (NASDAQ:OMER) Releases Earnings Results, Beats Estimates By $3.69 EPS](https://longbridge.com/en/news/281282968.md)